Program evaLuating the Autoimmune Disease iNvEstigational Drug cT-p13 in RA Patients(PLANETRA)
Status:
Completed
Trial end date:
2012-07-01
Target enrollment:
Participant gender:
Summary
This is the trial to see how our product is similar to remicade by comparing the results of
blood samples when co-administered with methotrexate between 12.5 to 25 mg/week, oral or
parenteral dose and folic acid in rheumatoid arthritis patients who are not receiving
adequate response to methotrexate alone up to week 30.